Cyprus vs United States: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Cyprus
83.0%
in 2025
United States
84.0%
in 2025
Cyprus rank
102nd
United States rank
100th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Cyprus
- United States
How they compare
United States currently reports 84.0% against 83.0% in Cyprus, a difference of 1.0%.
Across all 18 years both countries report, United States has been ahead every year.
Cyprus ranks 102nd and United States ranks 100th of 192 countries.
United States has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Cyprus | United States | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 93.0% | 93.0% | United States |
| 2010s | 40.5% | 92.6% | 52.1% | United States |
| 2020s | 80.3% | 83.3% | 3.0% | United States |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Cyprus or United States?
- United States, at 84.0% against 83.0% in Cyprus as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Cyprus and United States?
- 1.0%, with United States ahead.
- How many years of comparable data are there for Cyprus and United States?
- 18 years are reported by both, from 2008 to 2025.
- How do Cyprus and United States rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Cyprus ranks 102nd and United States ranks 100th of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.